| A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women |
17 |
| Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis |
16 |
| Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years |
15 |
| Pustular DRESS Syndrome Secondary to Hydroxychloroquine With EBV Reactivation |
13 |
| A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy |
11 |
| Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase Randomized, Double-Blind Clinical Trials |
10 |
| Dermatology on Instagram: An Analysis of Hashtags |
10 |
| Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL |
9 |
| Artificial Intelligence for the Objective Evaluation of Acne Investigator Global Assessment |
9 |
| Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials |
8 |
| A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne |
8 |
| Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis |
8 |
| Frequency of Treatment Switching for Spironolactone Compared to Oral Tetracycline-Class Antibiotics for Women With Acne: A Retrospective Cohort Study 2010-2016 |
8 |
| Cortexolone 17 alpha-propionate (Clascoterone) Is a Novel Androgen Receptor Antagonist that Inhibits Production of Lipids and Inflammatory Cytokines from Sebocytes In Vitro |
8 |
| Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis |
8 |
| Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study |
8 |
| Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials |
8 |
| Tavaborole 5% Topical Solution for the Treatment of Toenail Onychomycosis in Pediatric Patients: Results from a Phase 4 Open-Label Study |
8 |
| High Intensity Focused Electro-Magnetic Technology (HIFEM) for Non-Invasive Buttock Lifting and Toning of Gluteal Muscles: A Multi-Center Efficacy and Safety Study |
8 |
| Dupilumab Treatment for Prurigo Nodularis and Pruritis |
7 |
| Facial Safe Zones for Soft Tissue Filler Injections: A Practical Guide |
7 |
| Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase Dose-Ranging Study |
7 |
| Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study |
7 |
| A Phase Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris |
6 |
| Knowledge, Attitudes, and Perceptions of Cannabinoids in the Dermatology Community |
6 |
| Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies |
6 |
| A Six-Month, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of a Nutraceutical Supplement for Promoting Hair Growth in Women With Self-Perceived Thinning Hair |
6 |
| Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review |
6 |
| The Effect of Calcipotriene-Betamethasone Dipropionate Aerosol Foam versus Vehicle on Target Lesions in Moderate Severity Plaque Psoriasis: Focus on Elbows and Knees |
5 |
| Hybrid Fractional Laser: A Multi-Center Trial on the Safety and Efficacy for Photorejuvenation |
5 |
| Oral Collagen Supplementation: A Systematic Review of Dermatological Applications |
5 |
| IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A |
5 |
| Update on the Treatment of Scars |
5 |
| Patient-Reported Outcomes in Acne Patients With Skin of Color Using Adapalene 0.3%-Benzoyl Peroxide 2.5%: A Prospective Real-World Study |
5 |
| Clinical Validation of the Surface Volume Coefficient for Minimally Invasive Treatment of the Temple |
5 |
| Connecting the Dots: From Skin Barrier Dysfunction to Allergic Sensitization, and the Role of Moisturizers in Repairing the Skin Barrier |
5 |
| The Male Aesthetic Patient: Facial Anatomy, Concepts of Attractiveness, and Treatment Patterns |
5 |
| A Multi-Center, Open-Label, Prospective Study of Cannula Injection of Small-Particle Hyaluronic Acid Plus Lidocaine (SPHAL) for Lip Augmentation |
5 |
| Retinoids in Acne Management: Review of Current Understanding, Future Considerations, and Focus on Topical Treatments |
5 |
| Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis |
4 |
| Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older |
4 |
| Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis |
4 |
| Clinical Characteristics of Lower Extremity Surgical Site Infections in Dermatologic Surgery Based Upon 24-Month Retrospective Review |
4 |
| Safety and Efficacy of a 1550nm/1927nm Dual Wavelength Laser for the Treatment of Photodamaged Skin |
4 |
| Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab |
4 |
| Combination Ablative Approach to Laser Therapy in Advanced Aging of the Face |
4 |
| Efficacy and Safety of Toreforant, a Selective Histamine H-4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial |
4 |
| Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0% |
4 |
| Beyond Traditional Treatment: The Importance of Psychosocial Therapy in Vitiligo |
4 |
| Successful Treatment of Pemphigus Vulgaris With Ofatumumab |
4 |
